The event, part of the #CheckYourFoodTube campaign, was held in Cincinnati, Ohio.
Lucid Diagnostics launched its first-ever #CheckYourFoodTube Precancer Testing Event in Cincinnati, Ohio.1 The campaign is focused on educating the connection between gastroesphageal reflux disease and esophageal cancer. The disease is more commonly known as chronic heartburn,
The campaign is targeted at former NFL players. The first event featured an educational section, which was followed by on-site testing for the former players.
In a press release, former Cincinnati Bengals player and team leader of the Sports-Health Alliance at Russo Partners Solomon Wilcots said, “Collaborating with Lucid Diagnostics on this inaugural event is just the beginning of what we hope will be a game-changing initiative for former NFL players across the country. As athletes who've put our bodies on the line throughout our careers, we have a heightened awareness of the importance of protecting our long-term health. EsoGuard offers us a crucial opportunity for early detection of esophageal precancer, which can truly be a lifesaver. I strongly encourage all my peers in the sports community to take proactive steps in safeguarding their health from this deadly, yet preventable cancer. Remember, when it comes to esophageal cancer, early detection is the best—it's time we all 'Check Our Food Tubes!'"
Lucid chairman and CEO Lishan Aklog added, “These educational and precancer testing events targeting former NFL players provide us with a great opportunity to increase awareness of highly lethal but now preventable esophageal cancer. Individuals with heartburn and other risk factors (age over 50, male, white race, obesity, smoking, or a family history), whether former NFL players or their legions of fans, can now undergo a quick and simple test to determine whether they may have precancer and take appropriate steps to prevent this cancer. We are committed to getting the word out and appreciate Mr. Wilcots and his compatriots using their platform to help us do so."
Lucid also recently signed a memorandum of understanding with Front Line Mobile Health.2 This partnership will result in co-marketing initiatives targeted at firefighters.
In a press release issued in early September, Lucid president and chief operating officer Shaun O’Neil said, “Lucid Diagnostics is committed to widespread early detection of esophageal precancer. We are honored to have provided EsoGuard precancer testing to thousands of firefighters across the nation. Every day they risk their lives to protect us, and Lucid is committed to protecting them in return. This partnership allows us to expand these efforts by leveraging Front Line's resources and extensive expertise caring for firefighters. We are excited to further collaborate with Front Line to increase access to esophageal precancer testing for firefighters and drive revenue through contracted high-volume testing events."
In the same press release, Front Line team principal and CEO Russell A. Burnham added, “At Front Line Mobile Health, we are deeply committed to protecting the health and safety of our nation's firefighters, who face a 62% higher risk of developing esophageal cancer. Lucid's EsoGuard Esophageal DNA Test is a powerful tool in this endeavor, offering early detection of esophageal precancer and thereby safeguarding the well-being of these brave individuals. We look forward to expanding our partnership with Lucid and leveraging our strong relationships with fire departments to broaden access to this potentially life-saving tool."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.